What is Myriad Genetics's stock-based comp?

Myriad Genetics (MYGN) reported stock-based comp of $6.5M in Q1 2026.

How has Myriad Genetics's stock-based comp changed year-over-year?

Myriad Genetics's stock-based comp decreased by 31.6% year-over-year, from $9.5M to $6.5M.

What is the long-term trend for Myriad Genetics's stock-based comp?

Over 4 years (2021 to 2025), Myriad Genetics's stock-based comp has grown at a -0.8% compound annual growth rate (CAGR), from $36.3M to $35.2M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Myriad Genetics MYGN Stock-Based Comp

Stock-Based Comp at other companies

Labcorp HoldingsLH

$31.7M-3.4%

Quest DiagnosticsDGX

$20M-9.1%

NeoGenomicsNEO

$9.64M-10.4%

VeracyteVCYT

$12.76M+16.5%

Guardant HealthGH

$47.61M+26.1%

Natera, Inc.NTRA

$95.11M+22.2%

Other financials

Income statement

See full

Revenue$200.4M+2.3%

Gross profit$137.6M+2.5%

Operating income-$30.7M-5.9%

Net income-$34.1M-34,000%

EPS (diluted)-$0.36—

Balance sheet

See full

Cash & equivalents$126.0M+24.8%

Total debt$211.5M+34.2%

Total equity$337.4M-52.1%

Total assets$673.7M-33.0%

Cash flow

See full

Operating cash flow-$15.7M+3.7%

CapEx$18.8M+181%

Free cash flow-$19.7M+65.1%

Valuation

See full

Market cap$512.85M+13.1%

Enterprise value$598.35M+17.3%

P/S0.6×+0.1×

Profitability

See full

Gross margin70%0.0pp

Operating margin-46.9%-88.3pp

Net margin-48.2%-72.9pp

FCF margin-17%—

Returns & leverage

See full

Return on equity-76.7%-98.4pp

Debt / equity0.6×+0.4×

Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Myriad Genetics's stock-based comp?: Myriad Genetics (MYGN) reported stock-based comp of $6.5M in Q1 2026.
How has Myriad Genetics's stock-based comp changed year-over-year?: Myriad Genetics's stock-based comp decreased by 31.6% year-over-year, from $9.5M to $6.5M.
What is the long-term trend for Myriad Genetics's stock-based comp?: Over 4 years (2021 to 2025), Myriad Genetics's stock-based comp has grown at a -0.8% compound annual growth rate (CAGR), from $36.3M to $35.2M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.